胃癌组织KAI 1和nm23-H_1蛋白的表达意义

Clinicopathological significance of KAI 1 and nm23-H_1 expression in gastric cancer

目的:观察胃癌组织中KAI 1和nm23-H1蛋白的表达与临床病理生物学的关系,探讨KAI 1蛋白在胃癌发生、发展中的作用．方法:应用兔抗人KAI 1多克隆抗体和鼠抗人nm23-H1 单克隆抗体对87例手术切除胃癌标本以PV-9000免疫组化二步法进行染色,用x2检验进行统计学分析．结果:伴有淋巴结转移的胃癌组织中KAI 1蛋白表达阳性率(60％,39／65)明显低于无淋巴结转移的胃癌组织(95％,21／22,P<0．05),早中期胃癌组织中KAI 1蛋白表达阳性率(94％,16／17)显著高于晚期胃癌组织(63％, 44／70,P<0．05),KAI 1蛋白高表达者其生存期亦较长 (P<0．05);伴有淋巴结转移的胃癌组织中nm23-H1蛋白表达阳性率明显低于无淋巴结转移的胃癌组织(18％ vs 77％,P<0．05),早中期胃癌组织nm23-H1蛋白表达阳性率明显高于晚期胃癌组织(65％vs26％,P<0．05)．结论:KAI 1和nm23-H1蛋白均与胃癌侵袭转移有关, 且KAI 1表达与胃癌患者预后密切相关,将两种指标联合检测,可作为正确判断胃癌患者预后,指导临床治疗的分子生物学指标．

AIM： To investigate the expression of KAI 1 and nm23-H1 protein in gastric cancer, and to explore the clinicopathological significance of KAI 1 protein in the progression of gastric cancer. METHODS： Eighty-seven paraffin-embedded specimens of gastric cancer were investigated immunohistochemically by Envision method with rabbit anti-human KAI 1 polyclonal antibody and mouse anti-human nm23-H1 monoclonal antibody, Statistical analysis was performed using chi-square test, RESULTS： The positive rate of KAI 1 expression in gastric cancer with lymph node metastasis （60%, 39/65） was significantly lower than that without lymph node metastasis （95%, 21/22, P 〈0.05）, but the rate was markedly higher in early-stage tissues of gastric cancer than that in late-stage ones （94%, 16117 vs 63%, 44/70, P 〈0.05）. The patients with KAI 1 positive tumor tended to have a longer survival time （P 〈0.05）. The expression of nm23-H1 was notably decreased in gastric cancer with lymph node metastasis in comparison with that without lymph node metastasis （18% vs77%, P 〈0.05）, but nm23-H1 expression rate in early- and meta-phase gastric cancers was higher than that in late-phase gastric cancers （65% vs 26%, P 〈0.05）. CONCLUSION： KAI 1 and nm23-H1 are both associated with invasive ability of gastric cancer. Furthermore, KAI 1 is correlated with prognosis of patients with gastric cancers. Combined detection of KAI 1 and nm23-H1 may be helpful in predicting the prognosis and further directing the clinical therapy of gastric cancer.